Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Shin-ichi Satoh, Ichiro Ikegaki, Koh Kawasaki, Toshio Asano and Masato Shibuya
Affiliation: Scientific Affairs Dept., Asahi Kasei Pharma Corporation, 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo 101- 8101, Japan.
There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a
target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is
fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for
subarachnoid hemorrhage (SAH). A number of pathological processes, in particular hemodynamic dysfunctions and inflammatory
reactions, are thought to be related in the pathogenesis of delayed cerebral vasospasm and subsequent
ischemic injury after SAH. This review focuses on fasudil’s pleiotropic therapeutic effects: amelioration of hemodynamic
dysfunction and inflammation, and discusses in detail the clinical studies on fasudil administered after the occurrence of
Keywords: Cerebral vasospasm, fasudil, hydroxyfasudil, pleiotropic therapeutic effects, Rho-kinase, subarachnoid hemorrhage.
Rights & PermissionsPrintExport